Important treatments await the approval of the European Medicines Agency – Print

The treatment of eosinophilic asthma in children may soon be done by biological therapy, and a drug for the treatment of lung cancer in inoperable patients will soon be found in the European Union
GlaxoSmithKline (GSK), AstraZeneca and Bayer have separately received recommendations of major importance from a committee of the European Medicines Agency for the treatment of l & # 39; Severe asthma in children, lung cancer and anticoagulant medications, Reuters quoted news.ro The Committee for Medicinal Products for Human Use (CHMP) has recommended the use of GSK Nucal Drug to treat a severe form of eosinophilic asthma in patients aged 6 to 17 years. If approved, Nucala, which contains the substance Mepolizumab, would be the first targeted biological therapy to treat eosinophilic asthma in pediatric patients in Europe, according to GSK
AstraZeneca obtained the CHMP's recommendation for Imfinzi, an immunotherapeutic drug which has already boosted drug sales in the UK. The drug is intended for the treatment of lung cancer in inoperable, locally advanced patients without metastases. The US Administration of Drugs and Food approved in February the extension of the use of immunities to treat non-small cell lung cancer in patients who are inoperable with a medial disease without metastasis . Japan has also approved the drugs this month. Globally, approximately 30% of patients with this type of cancer have stage III disease. These patients usually receive a combination of chemotherapy and radiation therapy, but only 15% survive after five years. Bayer also received the recommendation of the European Medicines Agency for the widespread use of Xarelto to prevent blood clots, including patients with atherosclerosis, thus accessing a profitable market. The German drug maker estimated that about 30 million new patients could benefit from this drug if it is approved. These will be added to a population of about 25 million patients with atrial fibrillation, which is currently the most profitable market segment for Xarelto
The European Commission must give its final consent to the marketing of these drugs, but it generally conforms to the recommendation of the European Medicines Agency.

OD